Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775305 | 0.81 | ALDH1A1 (0.58) | ALDH1A1KDM4EPKMPOLBTSHR | |
| SCHEMBL7597949 | 0.81 | ALDH1A1 (0.52) | ALDH1A1KDM4EPKMPOLBTSHR | |
| SCHEMBL9446167 | 0.80 | ALDH1A1 (0.52) | ALDH1A1KDM4EPKMPOLBTSHR | |
| SCHEMBL14710756 | 0.80 | ALDH1A1 (0.52) | ALDH1A1KDM4EPKMPOLBTSHR | |
| SCHEMBL2775353 | 0.79 | TSHR (0.56) | ALDH1A1KDM4EPKMPOLBTSHR | |
| SCHEMBL20027632 | 0.79 | ALDH1A1 (0.51) | ALDH1A1KDM4EPKMPOLBTSHR | |
| SCHEMBL7597954 | 0.79 | ALDH1A1 (0.51) | ALDH1A1KDM4EPKMPOLBTSHR | |
| SCHEMBL15525136 | 0.79 | ALDH1A1 (0.55) | ALDH1A1KDM4EPKMPOLBTSHR | |
| SCHEMBL10821231 | 0.78 | ALDH1A1 (0.45) | ALDH1A1KDM4EPKMPOLBTSHR | |
| SCHEMBL9446171 | 0.77 | ALDH1A1 (0.50) | ALDH1A1KDM4EPKMPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428430-B2 | Oxabicyclo acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-30 | — | — | US | disclosed |
| EP-3853232-B1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2022-03-17 | — | — | US | disclosed |
| EP-3912975-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-11-24 | — | — | EP | disclosed |
| US-20210317131-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2021-10-14 | — | — | US | disclosed |
| CN-113366000-A | Oxabicyclic acids as LPA antagonists | 百时美施贵宝公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3853232-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020147739-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR | 武汉朗来科技发展有限公司 | 2020-07-23 | — | — | WO | disclosed |
| WO-2020060914-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-26 | — | — | WO | disclosed |
| US-9533977-B2 | Oxazolidinone derivative as CETP inhibitor, its preparation method, and pharmaceutical composition comprising the same | DONG-A ST CO., LTD. (KR) | 2017-01-03 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| US-6673824-B1 | HYPOTENSIVE AGENTS | BRISTOL-MYERS SQUIBB CO. | 2004-01-06 | — | — | US | disclosed |
| US-6107320-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0558258-B1 | N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists | SQUIBB & SONS INC (US) | 1997-05-07 | — | — | EP | disclosed |
| EP-0569193-B1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | SQUIBB & SONS INC (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5514696-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1996-05-07 | — | — | US | disclosed |
| US-5378715-A | Sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0569193-A1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-11-10 | — | — | EP | disclosed |
| EP-0558258-A1 | N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | ALDH1A1 4135/4885KDM4E 4418/4885PKM 2118/4885 |
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | LPAR1, LPAR2, LPAR4 | ALDH1A1 2782/4885KDM4E 3643/4885PKM 2099/4885 |
| US-12428430-B2 | Oxabicyclo acids as LPA antagonists | LPAR1, LPAR2, LPAR3 | ALDH1A1 1885/4885KDM4E 4479/4885PKM 2981/4885 |
| US-20210317131-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | LPAR1, LPAR2, LPAR3 | ALDH1A1 1885/4885KDM4E 4479/4885PKM 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.